Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes

Bibliography

• WILD S, ROGLIC G, GREEN A, SICREE R, KING H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-1053.
   PubMed Web of Science ®Google Scholar
• DEL PRATO S, MARCHETTI P: β- and α-cell dysfunction in Type 2 diabetes. Horm. Metab. Res. (2004) 36:775-781.
   PubMed Web of Science ®Google Scholar
• BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PC: β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52:102-110.
   PubMed Web of Science ®Google Scholar
• NATHAN DM, BUSE JB, DAVIDSON MB et al.: Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2006) 49:1711-1721.
   PubMed Web of Science ®Google Scholar
• HOLMAN RR: Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism (2006) 55(5 Suppl. 1):S2-S5.
   PubMed Web of Science ®Google Scholar
• KAHN SE, HAFFNER SM, HEISE MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. (2006) 355:2427-2443.
   PubMed Web of Science ®Google Scholar
• HOLST JJ: On the physiology of GIP and GLP-1. Horm. Metab. Res. (2004) 36:747-754.
   PubMed Web of Science ®Google Scholar
• NAUCK MA: Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Metab. Res. (2004) 36:852-858.
   PubMed Web of Science ®Google Scholar
• DEACON CF, HOLST JJ: Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of Type 2 diabetes. Int. J. Biochem. Cell Biol. (2006) 38:831-844.
   PubMed Web of Science ®Google Scholar
• DEACON CF, NAUCK MA, TOFT-NIELSEN M, PRIDAL L, WILLMS B, HOLST JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes (1995) 44:1126-1131.
   PubMed Web of Science ®Google Scholar
• DEACON CF: Therapeutic strategies based on glucagon-like peptide-1. Diabetes (2004) 53:2181-2189.
   PubMed Web of Science ®Google Scholar
• GÖKE R, FEHMANN HC, LINN T et al.: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. (1993) 268:19650-19655.
   PubMed Web of Science ®Google Scholar
• STONEHOUSE AH, HOLCOMBE JH, KENDALL DM: Management of Type 2 diabetes: the role of incretin mimetics. Expert Opin. Pharmacother. (2006) 7(15):2095-2105.
   PubMed Web of Science ®Google Scholar
• KNUDSEN LB, NIELSEN PF, HUUSFELDT PO et al.: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. (2000) 43:1664-1669.
   PubMed Web of Science ®Google Scholar
• KIM D, WANG L, BECONI M et al.: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48:141-151.
   PubMed Web of Science ®Google Scholar
• DEACON CF: MK-431 (Merck). Curr. Opin. Investig. Drugs (2005) 6:419-426.
   PubMedGoogle Scholar
• VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2003) 46:2774-2789.
   PubMed Web of Science ®Google Scholar
• AHRÉN B: Vildagliptin: an inhibitor of dipeptidyl pepidase-4 with antidiabetic properties. Expert Opin. Investig. Drugs (2006) 15(4):431-442.
   PubMed Web of Science ®Google Scholar
• NAUCK MA, KLEINE N, ØRSKOV C, HOLST JJ, WILLMS B, CREUTZFELDT W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 36:741-744.
   PubMed Web of Science ®Google Scholar
• NAUCK MA, WOLLSCHLÄGER D, WERNER J et al.: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia (1996) 39:1546-1553.
   PubMed Web of Science ®Google Scholar
• MENTLEIN R, GALLWITZ B, SCHMIDT WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitor peptide, glucagon-like peptide (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. (1993) 214:829-835.
   PubMedGoogle Scholar
• DEACON CF, JOHNSEN AH, HOLST JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. (1995) 80:952-957.
   PubMed Web of Science ®Google Scholar
• KIEFFER TJ, MCINTOSH CHS, PEDERSON RA: Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136:3585-3596.
   PubMed Web of Science ®Google Scholar
• DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes (1998) 47:764-769.
   PubMed Web of Science ®Google Scholar
• PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, MCINTOSH CH, DEMUTH HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253-1258.
   PubMed Web of Science ®Google Scholar
• AHREN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care (2002) 25:869-875.
   PubMed Web of Science ®Google Scholar
• LANKAS GR, LEITING B, ROY RS et al.: Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 54:2988-2994.
   PubMed Web of Science ®Google Scholar
• BARNETT A: DPP-4 inhibitors and their potential role in the management of Type 2 diabetes. Int. J. Clin. Pract. (2006) 60:1454-1470.
   PubMed Web of Science ®Google Scholar
• LAMBEIR AM, DURINX C, SCHARPE S, DE MEESTER I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPPIV. Crit. Rev. Clin. Lab. Sci. (2003) 40:209-294.
   PubMed Web of Science ®Google Scholar
• HUNZIKER D, HENNIG M, PETERS JU: Inhibitors of dipeptidyl peptidase IV – recent advances and structural views. Curr. Top. Med. Chem. (2005) 5:1623-1637.
   PubMed Web of Science ®Google Scholar
• HERMAN GA, BERGMAN A, WAGNER JA: Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug–drug interactions (DDI). Diabetologia (2006) 49(Suppl. 1):481 (Abstract).
   Google Scholar
• HERMAN GA, STEVENS C, VAN DYCK K et al.: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther. (2005) 78:675-688.
   PubMed Web of Science ®Google Scholar
• BERGMAN AJ, STEVENS C, ZHOU Y et al.: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin. Ther. (2006) 28:55-72.
   PubMed Web of Science ®Google Scholar
• HERMAN GA, BERGMAN A, LIU F et al.: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol. (2006) 46:876-886.
   PubMed Web of Science ®Google Scholar
• BERGMAN AJ, STEVENS C, YI B et al.: Lack of a clinically meaningful effect of age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431. Diabetes (2005) 54(Suppl. 1):A506 (Abstract).
   Google Scholar
• HERMAN GA, BERGMAN A, STEVENS C et al.: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2006) 91:4612-4619.
   PubMed Web of Science ®Google Scholar
• STEVENS C, BERGMAN A, LIU Q et al.: Lack of clinical significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl peptidase-IV (DPP-IV) inhibitor. Clin. Pharmacol. Ther. (2006) 79:P49 (Abstract).
   PubMed Web of Science ®Google Scholar
• SCOTT R, WU M, SANCHEZ M, STEIN P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with Type 2 diabetes. Int. J. Clin. Pract. (2007) 61:171-180.
   PubMed Web of Science ®Google Scholar
• HERMAN G, HANEFELD M, WU M, CHEN X, ZHAO P, STEIN P: Effect of MK-0431 (sitagliptin), a dipeptidyl peptidase (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with Type 2 diabetes. Diabetes (2005) 54(Suppl. 1):A134 (Abstract).
   Google Scholar
• RAZ I, HANEFELD M, XU L, CARIA C, WILLIAMS-HERMAN D, KHATAMI H: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia (2006) 49:2564-2571.
   PubMed Web of Science ®Google Scholar
• ASCHNER P, KIPNES M, LUNCEFORD M, SANCHEZ M, MICKEL C, WILLIAMS-HERMAN DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care (2006) 29:2632-2637.
   PubMed Web of Science ®Google Scholar
• NONAKA K, KAKIKAWA T, SATO A et al.: Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, as monotherapy in Japanese patients with Type 2 diabetes. Diabetes (2006) 55(Suppl. 1):A128 (Abstract).
   PubMed Web of Science ®Google Scholar
• CHARBONNEL B, KARASIK A, LIU J, WU M, MEININGER G: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care (2006) 29:2638-2643.
   PubMed Web of Science ®Google Scholar
• WILLIAMS-HERMAN D, GOLDSTEIN BJ, FEINGLOS MN, LUNCEFORD, JOHNSON J: Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin provides substantial glycemic improvement and Hba1c goal attainment in patients with Type 2 diabetes mellitus (T2DM). Diab. Med. (2006) 23(Suppl. 4):319 (Abstract).
   Google Scholar
• ROSENSTOCK J, BRAZG R, ANDRYUK PJ, LU K, STEIN P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with Type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. (2006) 28:1556-1568.
   PubMed Web of Science ®Google Scholar
• NAUCK M, MEININGER G, SHENG D, TERRANELLA L, STEIN P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diab. Obesity Metab. (2007) 9(2):194-205.
   PubMed Web of Science ®Google Scholar
• HERMAN GA, BERGMAN A, YI B, KIPNES M: Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with Type 2 diabetes. Curr. Med. Res. Opin. (2006) 22:1939-1947.
   PubMed Web of Science ®Google Scholar
• MISTRY G, BERGMAN A, LUO WL et al.: Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J. Clin. Pharmacol. (2007) 47:159-164.
   PubMed Web of Science ®Google Scholar
• RUDDY MK, BERGMAN AJ, ZHENG W et al.: Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea glyburide. Diabetes (2006) 55(Suppl. 1):A133 (Abstract).
   Google Scholar
• TOFT-NIELSEN MB, DAMHOLT MB, MADSBAD S et al.: Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86:3717-3723.
   PubMed Web of Science ®Google Scholar
• RATNER RE, STONEHOUSE A, GAO HY, POON T, KIM D: Exenatide maintains glycemic control for 2 years in patients with Type 2 diabetes: data from an ongoing, open-label study. Diabetologia (2005) 48(Suppl. 1):A288 (Abstract).
   Google Scholar
• RASK E, OLSSON T, SODERBERG S et al.: Impaired incretin response after a mixed meal is associated with insulin resistance in non-diabetic men. Diabetes Care (2001) 24:1640-1645.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, BARON MA, SCHWEIZER A, MILLS D, DEJAGER S: Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with Type 2 diabetes (T2DM). Diabetes (2006) 55(Suppl. 1):A133 (Abstract).
   Google Scholar
• XU G, STOFFERS DA, HABENER JF, BONNER-WEIR S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48:2270-2276.
   PubMed Web of Science ®Google Scholar
• FARILLA L, BULOTTA A, HIRSCHBERG B et al.: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology (2003) 144:5149-5158.
   PubMed Web of Science ®Google Scholar
• DUTTEROY A, VOELKER F, ZHANG X et al.: The DPP-4 inhibitor vildagliptin increases pancreatic β cell mass in rodents. Diabetologia (2005) 48(Suppl. 1):A178 (Abstract).
   Google Scholar
• MU J, WOODS J, ZHOU YP et al.: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of Type 2 diabetes. Diabetes (2006) 55:1695-1704.
   PubMed Web of Science ®Google Scholar